Press Releases :: Ligand Pharmaceuticals Incorporated (LGND)

Press Releases

Ligand’s Partner Melinta Therapeutics Announces U.S. FDA Approval of Baxdela™ (Delafloxacin) for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

June 20, 2017

Ligand Enters into Worldwide OmniAb® Platform License Agreement with Surface Oncology

June 1, 2017

Ligand Announces Aziyo Biologics Acquires Commercial Products from Partner CorMatrix

May 31, 2017

Ligand Enters Into Worldwide OmniAb® Platform License Agreement With xCella Biosciences

May 30, 2017

Ligand to Participate in Two Upcoming Investor Conferences

May 22, 2017

Ligand Reports First Quarter 2017 Financial Results

May 9, 2017

Ligand to Report First Quarter 2017 Results on May 9th

April 13, 2017

Ligand Enters Commercial License and Supply Agreements with Marinus Pharmaceuticals for Captisol-Enabled Ganaxolone

April 5, 2017

Ligand Announces Licensing Partner Janssen Has Filed an IND for an Antibody Discovered Using the OmniAb® Technology

March 28, 2017

Ligand to Participate in Upcoming Investor Conference

March 9, 2017

Ligand Provides Highlights from Today’s Analyst Day Event

February 28, 2017

Ligand Expands License with Sermonix to Include Worldwide Rights for Oral Lasofoxifene

February 28, 2017

Enrollment Completed in Ligand’s Phase 2 Trial of LGD-6972 in Type 2 Diabetes

February 27, 2017

Ligand Reports Fourth Quarter and Full Year 2016 Financial Results

February 23, 2017

Dr. Christel Iffland Joins Ligand as Vice President, Antibody Technologies, Expands Team Focused on OmniAb Drug Discovery Platform

February 14, 2017